Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrins

Renu Bhardwaj, Robert T Dorr, James Blanchard

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Mitomycin C (MMC) is a clinically useful anticancer drug which can cause severe dermatological problems upon injection. It can cause delayed erythema and/or ulceration occurring either at or distant from the injection site for weeks or even months after administration. In an attempt to reduce the skin necrosis, complexation of MMC with cyclodextrins was studied in order to help increase patient compliance and acceptance. The complexation of MMC with 2- Hydroxypropylbetacyclodextrin (HPBCD) in the presence and absence of mannitol was studied and it was found that the mannitol present in the commercial formulation caused an increase in the binding of MMC to HPBCD. Isotonicity adjustment of hypotonic MMC formulations by the addition of normal saline did not change the degree of complexation with MMC. The complexed formulations were then tested to determine their antitumor efficacy using the B-16 melanoma cell model. No difference in antitumor activity between the complexed and uncomplexed MMC formulations was observed. Different MMC formulations were tested for their potential to produce skin irritation and/or toxicity using intradermal injections in a BALB/c mouse model in order to find the most suitable formulation. The skin ulceration studies indicated that there were no significant differences between the isotonic MMC solution and isotonic formulations of MMC complexed with HPBCD.

Original languageEnglish (US)
Pages (from-to)233-239
Number of pages7
JournalPDA Journal of Pharmaceutical Science and Technology
Volume54
Issue number3
StatePublished - May 2000
Externally publishedYes

Fingerprint

Drug Compounding
Cyclodextrins
Mitomycin
Mannitol
Skin
Isotonic Solutions
Social Adjustment
Intradermal Injections
Injections
Erythema
Patient Compliance
Melanoma
Necrosis

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrins. / Bhardwaj, Renu; Dorr, Robert T; Blanchard, James.

In: PDA Journal of Pharmaceutical Science and Technology, Vol. 54, No. 3, 05.2000, p. 233-239.

Research output: Contribution to journalArticle

@article{f13558739e4a44a9bfea52d7a6beb875,
title = "Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrins",
abstract = "Mitomycin C (MMC) is a clinically useful anticancer drug which can cause severe dermatological problems upon injection. It can cause delayed erythema and/or ulceration occurring either at or distant from the injection site for weeks or even months after administration. In an attempt to reduce the skin necrosis, complexation of MMC with cyclodextrins was studied in order to help increase patient compliance and acceptance. The complexation of MMC with 2- Hydroxypropylbetacyclodextrin (HPBCD) in the presence and absence of mannitol was studied and it was found that the mannitol present in the commercial formulation caused an increase in the binding of MMC to HPBCD. Isotonicity adjustment of hypotonic MMC formulations by the addition of normal saline did not change the degree of complexation with MMC. The complexed formulations were then tested to determine their antitumor efficacy using the B-16 melanoma cell model. No difference in antitumor activity between the complexed and uncomplexed MMC formulations was observed. Different MMC formulations were tested for their potential to produce skin irritation and/or toxicity using intradermal injections in a BALB/c mouse model in order to find the most suitable formulation. The skin ulceration studies indicated that there were no significant differences between the isotonic MMC solution and isotonic formulations of MMC complexed with HPBCD.",
author = "Renu Bhardwaj and Dorr, {Robert T} and James Blanchard",
year = "2000",
month = "5",
language = "English (US)",
volume = "54",
pages = "233--239",
journal = "PDA Journal of Pharmaceutical Science and Technology",
issn = "1079-7440",
publisher = "Parenteral Drug Association Inc.",
number = "3",

}

TY - JOUR

T1 - Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrins

AU - Bhardwaj, Renu

AU - Dorr, Robert T

AU - Blanchard, James

PY - 2000/5

Y1 - 2000/5

N2 - Mitomycin C (MMC) is a clinically useful anticancer drug which can cause severe dermatological problems upon injection. It can cause delayed erythema and/or ulceration occurring either at or distant from the injection site for weeks or even months after administration. In an attempt to reduce the skin necrosis, complexation of MMC with cyclodextrins was studied in order to help increase patient compliance and acceptance. The complexation of MMC with 2- Hydroxypropylbetacyclodextrin (HPBCD) in the presence and absence of mannitol was studied and it was found that the mannitol present in the commercial formulation caused an increase in the binding of MMC to HPBCD. Isotonicity adjustment of hypotonic MMC formulations by the addition of normal saline did not change the degree of complexation with MMC. The complexed formulations were then tested to determine their antitumor efficacy using the B-16 melanoma cell model. No difference in antitumor activity between the complexed and uncomplexed MMC formulations was observed. Different MMC formulations were tested for their potential to produce skin irritation and/or toxicity using intradermal injections in a BALB/c mouse model in order to find the most suitable formulation. The skin ulceration studies indicated that there were no significant differences between the isotonic MMC solution and isotonic formulations of MMC complexed with HPBCD.

AB - Mitomycin C (MMC) is a clinically useful anticancer drug which can cause severe dermatological problems upon injection. It can cause delayed erythema and/or ulceration occurring either at or distant from the injection site for weeks or even months after administration. In an attempt to reduce the skin necrosis, complexation of MMC with cyclodextrins was studied in order to help increase patient compliance and acceptance. The complexation of MMC with 2- Hydroxypropylbetacyclodextrin (HPBCD) in the presence and absence of mannitol was studied and it was found that the mannitol present in the commercial formulation caused an increase in the binding of MMC to HPBCD. Isotonicity adjustment of hypotonic MMC formulations by the addition of normal saline did not change the degree of complexation with MMC. The complexed formulations were then tested to determine their antitumor efficacy using the B-16 melanoma cell model. No difference in antitumor activity between the complexed and uncomplexed MMC formulations was observed. Different MMC formulations were tested for their potential to produce skin irritation and/or toxicity using intradermal injections in a BALB/c mouse model in order to find the most suitable formulation. The skin ulceration studies indicated that there were no significant differences between the isotonic MMC solution and isotonic formulations of MMC complexed with HPBCD.

UR - http://www.scopus.com/inward/record.url?scp=0033940697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033940697&partnerID=8YFLogxK

M3 - Article

C2 - 10927914

AN - SCOPUS:0033940697

VL - 54

SP - 233

EP - 239

JO - PDA Journal of Pharmaceutical Science and Technology

JF - PDA Journal of Pharmaceutical Science and Technology

SN - 1079-7440

IS - 3

ER -